{"success":true,"data":{"pressRelease":{"id":"158586","rtpr_id":"nGNXbbhZT3-20261001","ticker":"TRNG","exchange":"Euronext Paris","all_tickers":["TRNG"],"title":"Transgene to Participate in Investor Access","author":"Globe Newswire","published_at":"2026-10-01T15:45:00.358Z","article_body":"Strasbourg, France, October 1, 2026, 5:45 pm CET — Transgene (Euronext\nParis: TNG), a biotech company developing myvac®, an individualized\nneoantigen therapeutic vaccines (INTV) platform designed to prevent cancer\nrecurrence together with a portfolio of virus-based candidates, today\nannounced that its management team will meet institutional investors during\nthe upcoming edition of Investor Access Event (by Investor Access), on October\n6, 2026, in Paris.\n\nOrganized by Investor Access, these events connect listed companies with\nprofessional investors through targeted, pre-arranged meetings with management\nteams. The 2026 program brings together more than 190 professional investors\nand 90 listed companies across its events.\n\nDuring the event, Transgene will discuss progress with its myvac® platform\nincluding TG4050 in head and neck cancer and TG4070 in non-small cell lung\ncancer as well as other virus-based programs from its emerging pipeline.\nOrganized by Investor Access, these events connect listed companies with\nprofessional investors through targeted, pre-arranged meetings with management\nteams. The 2026 program brings together more than 190 professional investors\nand 90 listed companies across its events.\n\n***\n\nContacts\n\n Transgene:                                                                       \n Media:                                           Investors & Analysts:           \n Caroline Tosch-Pourchot                          Lucie Larguier                  \n Corporate and Scientific Communications Manager  Chief Financial Officer (CFO)   \n +33 (0)3 68 33 27 38                             +33 (0)3 88 27 91 00/21         \n communication@transgene.fr                       investorrelations@transgene.fr  \n MEDiSTRAVA                                                                       \n Frazer Hall/Sylvie Berrebi                                                       \n + 44 (0)203 928 6900                                                             \n transgene@medistrava.com                                                         \n\n \n\nAbout Transgene\nTransgene (Euronext: TNG) is a biotechnology company focused on designing and\ndeveloping virus-based targeted immunotherapies and vaccines. The Company’s\nclinical-stage programs consist of a portfolio of viral vector-based\nimmunotherapeutics. Transgene’s myvac® platform is designed to develop\nindividualized neoantigen therapeutic vaccines (INTVs), with potential across\nmultiple solid tumor types.\nTG4050, the first INTV based on the myvac® platform is the Company’s lead\nasset, with demonstrated clinical proof of principle in the adjuvant treatment\nof head and neck cancer. TG4070, the second myvac®-based INTV introduces\nTransgene’s proprietary AI-driven neoantigen selection and scalable\ncell-line manufacturing capabilities and is in Phase 1 clinical development\nin combination with nivolumab in the adjuvant treatment of non-small cell lung\ncancer (NSCLC). The Company’s other viral vector-based assets include\nBT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in\nclinical development. Transgene also conducts innovative discovery and\npreclinical work, aimed at developing novel viral vector-based modalities. \nWith Transgene’s myvac® platform, therapeutic vaccination enters the field\nof precision medicine with an immunotherapy tailored to each individual\npatient. The myvac® approach enables the generation of virus-based\nimmunotherapies encoding patient-specific neoantigens. Transgene has further\nexpanded the platform’s capabilities with its own proprietary AI-driven\nneoantigen selection and scalable cell-line manufacturing.\nLeveraging its MVA and cell-line manufacturing expertise, Transgene is\ndeveloping TG-MVA™, a next-generation prophylactic vaccine candidate against\nmpox and smallpox designed to address key manufacturing and supply challenges.\nWith its proprietary Invir.IO® platform, Transgene is building on its viral\nvector engineering expertise to design a new generation of multifunctional\noncolytic viruses.\nAdditional information about Transgene is available at: www.transgene.com\nFollow us on social media: LinkedIn: @Transgene — X: @TransgeneSA —\nBluesky: @Transgene\n\nDisclaimer \nThis press release contains forward-looking statements, which are subject to\nnumerous risks and uncertainties, which could cause actual results to differ\nmaterially from those anticipated. The occurrence of any of these risks could\nhave a significant negative outcome for the Company’s activities,\nperspectives, financial situation, results, regulatory authorities’\nagreement with development phases, and development. The Company’s ability to\ncommercialize its products depends on but is not limited to the following\nfactors: positive pre-clinical data may not be predictive of human clinical\nresults, the success of clinical studies, the ability to obtain financing\nand/or partnerships for product manufacturing, development and\ncommercialization, and marketing approval by government regulatory\nauthorities. For a discussion of risks and uncertainties which could cause the\nCompany’s actual results, financial condition, performance or achievements\nto differ from those contained in the forward-looking statements, please refer\nto the Risk Factors (“Facteurs de Risque”) section of the Universal\nRegistration Document, available on the AMF website\n(http://www.amf-france.org) or on Transgene’s website (www.transgene.com).\nForward-looking statements speak only as of the date on which they are made,\nand Transgene undertakes no obligation to update these forward-looking\nstatements, even if new information becomes available in the future.\n\nAttachment\n*     20261001_InvestorAccess_EN\n(https://ml-eu.globenewswire.com/Resource/Download/63abe09a-ab91-4a14-b53c-42057f801d78)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/69cc3e2a-494a-44a6-bdc8-2771703de073)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbbhZT3-20261001","title":"Transgene to Participate in Investor Access","author":"Globe Newswire","ticker":"TRNG","created":"2026-10-01T15:45:00.358Z","tickers":["TRNG"],"exchange":"Euronext Paris","article_body":"Strasbourg, France, October 1, 2026, 5:45 pm CET — Transgene (Euronext\nParis: TNG), a biotech company developing myvac®, an individualized\nneoantigen therapeutic vaccines (INTV) platform designed to prevent cancer\nrecurrence together with a portfolio of virus-based candidates, today\nannounced that its management team will meet institutional investors during\nthe upcoming edition of Investor Access Event (by Investor Access), on October\n6, 2026, in Paris.\n\nOrganized by Investor Access, these events connect listed companies with\nprofessional investors through targeted, pre-arranged meetings with management\nteams. The 2026 program brings together more than 190 professional investors\nand 90 listed companies across its events.\n\nDuring the event, Transgene will discuss progress with its myvac® platform\nincluding TG4050 in head and neck cancer and TG4070 in non-small cell lung\ncancer as well as other virus-based programs from its emerging pipeline.\nOrganized by Investor Access, these events connect listed companies with\nprofessional investors through targeted, pre-arranged meetings with management\nteams. The 2026 program brings together more than 190 professional investors\nand 90 listed companies across its events.\n\n***\n\nContacts\n\n Transgene:                                                                       \n Media:                                           Investors & Analysts:           \n Caroline Tosch-Pourchot                          Lucie Larguier                  \n Corporate and Scientific Communications Manager  Chief Financial Officer (CFO)   \n +33 (0)3 68 33 27 38                             +33 (0)3 88 27 91 00/21         \n communication@transgene.fr                       investorrelations@transgene.fr  \n MEDiSTRAVA                                                                       \n Frazer Hall/Sylvie Berrebi                                                       \n + 44 (0)203 928 6900                                                             \n transgene@medistrava.com                                                         \n\n \n\nAbout Transgene\nTransgene (Euronext: TNG) is a biotechnology company focused on designing and\ndeveloping virus-based targeted immunotherapies and vaccines. The Company’s\nclinical-stage programs consist of a portfolio of viral vector-based\nimmunotherapeutics. Transgene’s myvac® platform is designed to develop\nindividualized neoantigen therapeutic vaccines (INTVs), with potential across\nmultiple solid tumor types.\nTG4050, the first INTV based on the myvac® platform is the Company’s lead\nasset, with demonstrated clinical proof of principle in the adjuvant treatment\nof head and neck cancer. TG4070, the second myvac®-based INTV introduces\nTransgene’s proprietary AI-driven neoantigen selection and scalable\ncell-line manufacturing capabilities and is in Phase 1 clinical development\nin combination with nivolumab in the adjuvant treatment of non-small cell lung\ncancer (NSCLC). The Company’s other viral vector-based assets include\nBT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in\nclinical development. Transgene also conducts innovative discovery and\npreclinical work, aimed at developing novel viral vector-based modalities. \nWith Transgene’s myvac® platform, therapeutic vaccination enters the field\nof precision medicine with an immunotherapy tailored to each individual\npatient. The myvac® approach enables the generation of virus-based\nimmunotherapies encoding patient-specific neoantigens. Transgene has further\nexpanded the platform’s capabilities with its own proprietary AI-driven\nneoantigen selection and scalable cell-line manufacturing.\nLeveraging its MVA and cell-line manufacturing expertise, Transgene is\ndeveloping TG-MVA™, a next-generation prophylactic vaccine candidate against\nmpox and smallpox designed to address key manufacturing and supply challenges.\nWith its proprietary Invir.IO® platform, Transgene is building on its viral\nvector engineering expertise to design a new generation of multifunctional\noncolytic viruses.\nAdditional information about Transgene is available at: www.transgene.com\nFollow us on social media: LinkedIn: @Transgene — X: @TransgeneSA —\nBluesky: @Transgene\n\nDisclaimer \nThis press release contains forward-looking statements, which are subject to\nnumerous risks and uncertainties, which could cause actual results to differ\nmaterially from those anticipated. The occurrence of any of these risks could\nhave a significant negative outcome for the Company’s activities,\nperspectives, financial situation, results, regulatory authorities’\nagreement with development phases, and development. The Company’s ability to\ncommercialize its products depends on but is not limited to the following\nfactors: positive pre-clinical data may not be predictive of human clinical\nresults, the success of clinical studies, the ability to obtain financing\nand/or partnerships for product manufacturing, development and\ncommercialization, and marketing approval by government regulatory\nauthorities. For a discussion of risks and uncertainties which could cause the\nCompany’s actual results, financial condition, performance or achievements\nto differ from those contained in the forward-looking statements, please refer\nto the Risk Factors (“Facteurs de Risque”) section of the Universal\nRegistration Document, available on the AMF website\n(http://www.amf-france.org) or on Transgene’s website (www.transgene.com).\nForward-looking statements speak only as of the date on which they are made,\nand Transgene undertakes no obligation to update these forward-looking\nstatements, even if new information becomes available in the future.\n\nAttachment\n*     20261001_InvestorAccess_EN\n(https://ml-eu.globenewswire.com/Resource/Download/63abe09a-ab91-4a14-b53c-42057f801d78)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/69cc3e2a-494a-44a6-bdc8-2771703de073)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-01T15:45:00.427798959Z","server_sent_at_ms":1790869500427},"received_at":"2026-10-01T15:45:00.480Z","source_url":null},"analysis":{"id":"147208","press_release_id":"158586","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Transgene announced that its management team will meet institutional investors at the Investor Access event in Paris on October 6, 2026.\n\nThe company plans to discuss progress with its myvac platform, including TG4050 in head and neck cancer and TG4070 in non-small cell lung cancer, alongside other virus-based pipeline programs.\n\nThe event is a routine investor-relations engagement with no new data or corporate developments disclosed.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor-conference participation by Transgene -- suppress unless new pipeline data emerges."},"keyFigures":{"customDimensions":{"companies_at_event":"90 listed companies","investors_at_event":"more than 190 professional investors"}},"namedEntities":{"people":[{"name":"Caroline Tosch-Pourchot","role":"Corporate and Scientific Communications Manager"},{"name":"Lucie Larguier","role":"Chief Financial Officer"}],"products":["myvac","TG4050","TG4070","BT-001","TG-MVA","Invir.IO","nivolumab"],"companies":[{"name":"Transgene","ticker":"TNG","relationship":"filer"},{"name":"Investor Access","relationship":"event organizer"},{"name":"MEDiSTRAVA","relationship":"media agency"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement that management will attend an investor access event in Paris. No new clinical, financial, or strategic information disclosed."},"tickerRelevance":{"others":[{"ticker":"TNG","relevance":"Euronext Paris listing of the same issuer"}],"primary":"TRNG"},"globalImportance":5,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"routine-investor-conference","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Transgene announced that its management team will meet institutional investors at the Investor Access event in Paris on October 6, 2026.\n\nThe company plans to discuss progress with its myvac platform, including TG4050 in head and neck cancer and TG4070 in non-small cell lung cancer, alongside other virus-based pipeline programs.\n\nThe event is a routine investor-relations engagement with no new data or corporate developments disclosed.","key_figures":{"customDimensions":{"companies_at_event":"90 listed companies","investors_at_event":"more than 190 professional investors"}},"named_entities":{"people":[{"name":"Caroline Tosch-Pourchot","role":"Corporate and Scientific Communications Manager"},{"name":"Lucie Larguier","role":"Chief Financial Officer"}],"products":["myvac","TG4050","TG4070","BT-001","TG-MVA","Invir.IO","nivolumab"],"companies":[{"name":"Transgene","ticker":"TNG","relationship":"filer"},{"name":"Investor Access","relationship":"event organizer"},{"name":"MEDiSTRAVA","relationship":"media agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T15:45:05.568Z","global_importance":5,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"routine-investor-conference","issuerAuthored":true}},"durationMs":5059,"modelName":"glm-5.3-flashx"}}